These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37828817)

  • 21. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
    Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
    Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
    Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
    Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
    Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life.
    Abdelhakiem MK; Keller A; Bajpai RR; Smith RP; Beriwal S; Benoit R
    Brachytherapy; 2023; 22(6):808-821. PubMed ID: 37648596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
    Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 May; 28(5):698-706. PubMed ID: 36814038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
    Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
    Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men.
    Li Y; Chan Kong Ngai T; Zhou S; Yap Haw Hwong J; Pang Pei Ping E; Ong Li Kuan A; Wang Lian Chek M; Chua Lee Kiang M; Looi WS; Nei WL; Chua ET; On WLK; Tan Wee Kiat T; Yuen Shyi Peng J; Tuan Kit Loong J
    Acta Oncol; 2021 Oct; 60(10):1291-1295. PubMed ID: 34259123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
    Zaorsky NG; Doyle LA; Hurwitz MD; Dicker AP; Den RB
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):39-50. PubMed ID: 24124755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.
    Burchardt W; Skowronek J
    J Contemp Brachytherapy; 2018 Feb; 10(1):1-9. PubMed ID: 29619050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Brachytherapy in men with prostate cancer: update on indications and outcomes].
    Pinto F; Calarco A; Recupero SM; Totaro A; Sacco E; Bassi P
    Urologia; 2013; 80(2):87-98. PubMed ID: 23852925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolution of brachytherapy for prostate cancer.
    Zaorsky NG; Davis BJ; Nguyen PL; Showalter TN; Hoskin PJ; Yoshioka Y; Morton GC; Horwitz EM
    Nat Rev Urol; 2017 Jun; 14(7):415-439. PubMed ID: 28664931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
    Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
    Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.
    Barnes J; Kennedy WR; Fischer-Valuck BW; Baumann BC; Michalski JM; Gay HA
    J Contemp Brachytherapy; 2019 Aug; 11(4):320-328. PubMed ID: 31523232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.